Bone mineral content after renal transplantation. Placebo-controlled prospective study with 1,25-dihydroxy vitamin D3.
Forearm bone mineral content (BMC), as evaluated by photonabsorption densitometry, was measured in 28 cadaver kidney donor recipients who entered the study 8 weeks postoperatively and were followed up for 18 months. BMC decreased significantly (p less than 0.05) but marginally in placebo-treated patients (n = 14) (initial BMC 1.09 +/- 0.25 g/cm; final BMC 1.05 +/- 0.24). Fourteen patients were prophylactically given 1,25(OH)2 vitamin D3 in a dose which avoided hypercalcemia and hypercalciuria (approximately 0.25 microgram/day); under 1,25(OH)2 vitamin D3 prophylaxis a significant decrease of forearm BMC was observed no longer (initial BMC 0.94 +/- 0.21 g/cm; final BMC 0.95 +/- 0.21), but the difference between placebo and 1,25(OH)2 vitamin D3 narrowly missed statistical significance (p = 0.066). It is concluded that the decrease of forearm BMC is negligible in transplant recipients with low steroid regimens. The data suggest a trend for prophylaxis with 1,25(OH)2 vitamin D3 to slightly ameliorate forearm (cortical) BMC loss.
D000328:Adult; D001847:Bone Diseases / Q000517:prevention & control; D001842:Bone and Bones / Q000032:analysis*; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003720:Densitometry; D005542:Forearm; D006801:Humans; D016030:Kidney Transplantation; D008775:Methylprednisolone / Q000627:therapeutic use; D008903:Minerals / Q000032:analysis*; D010919:Placebos; D011446:Prospective Studies; D011897:Random Allocation; D013997:Time Factors
D008903:Minerals; D010919:Placebos; C034777:1,25-dihydroxyvitamin D3 monoglucuronide; D002117:Calcitriol; D008775:Methylprednisolone